Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Shares Outstanding (Weighted Average): 2014-2025

Historic Shares Outstanding (Weighted Average) for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $112.4 million.

  • Viking Therapeutics' Shares Outstanding (Weighted Average) rose 1.49% to $112.4 million in Q3 2025 from the same period last year, while for Sep 2018 it was $60.7 million, marking a year-over-year increase of 119.00%. This contributed to the annual value of $111.4 million for FY2024, which is 11.40% up from last year.
  • Per Viking Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $112.4 million for Q3 2025, which was up 0.12% from $112.3 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Shares Outstanding (Weighted Average) registered a high of $112.4 million during Q3 2025, and its lowest value of $74.1 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $104.4 million, with a median of $110.3 million in 2024.
  • In the last 5 years, Viking Therapeutics' Shares Outstanding (Weighted Average) declined by 1.98% in 2022 and then surged by 30.44% in 2023.
  • Quarterly analysis of 5 years shows Viking Therapeutics' Shares Outstanding (Weighted Average) stood at $78.2 million in 2021, then decreased by 1.98% to $76.7 million in 2022, then soared by 30.44% to $100.0 million in 2023, then rose by 11.40% to $111.4 million in 2024, then climbed by 1.49% to $112.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $112.4 million for Q3 2025, versus $112.3 million for Q2 2025 and $112.2 million for Q1 2025.